Neuronetics Presents NeuroStar TMS at AACAP Annual Meeting
MALVERN, Pa. - Neuronetics, Inc. (NASDAQ: STIM), a leading medical technology company, has announced its participation in the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting. This event commenced today and will run until October 19th. Neuronetics is particularly excited to showcase its innovative NeuroStar Transcranial Magnetic Stimulation (TMS) System, along with an important oral presentation by Dr. Paul E. Croarkin scheduled for October 16th.
Highlighting Innovative Treatments for Mental Health
The focus of the upcoming presentation will center on an extensive study involving adolescents and young adults suffering from major depressive disorder (MDD) treated with TMS. The preliminary data reveal remarkable results, showing a 78% response rate and a 48% remission rate among the adolescent patients analyzed. Notably, the average improvement exceeded 10 points in depression symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9).
Significance of NeuroStar in Adolescent Treatment
Cory Anderson, the Senior Vice President of Research & Development and Clinical at Neuronetics, emphasized the crucial role that the NeuroStar TMS System plays for younger patients who have limited options for approved treatments. The NeuroStar system is clinically validated and FDA-cleared for treating adolescents aged 15 and up as an initial adjunct treatment for MDD.
Positive Clinical Outcomes Reinforced
Dr. Melissa Fickey, an AACAP member and board-certified psychiatrist, reinforced the favorable clinical outcomes that have been observed since the FDA clearance of NeuroStar for adolescent use earlier this year. This approval has been a significant milestone for the company.
The Future of NeuroStar Therapy
Neuronetics is dedicated to addressing mental health concerns with the same seriousness as physical health, striving to reshape how patients and healthcare providers view treatment expectations. The NeuroStar Advanced Therapy is non-experimental, noninvasive, and represents a pivotal advancement in mental health care options. Besides treating adolescents, the NeuroStar TMS System has also received FDA clearance for adults suffering from obsessive-compulsive disorder.
Interactive Demonstration and Further Engagement
During the AACAP meeting, Neuronetics will showcase the NeuroStar TMS System at booth #416. This hands-on demonstration aims to educate attendees about the benefits of TMS Therapy. For interested individuals seeking more information about NeuroStar TMS Therapy, Neuronetics encourages them to visit the company’s official website for comprehensive details.
Current Market Position and Financial Overview
Recently, Neuronetics reported a second-quarter revenue of $16.5 million, which unfortunately did not meet previous estimates. This discrepancy is attributed to changing purchasing behaviors likely influenced by industry developments, including the Change Health cyberattack. Despite these hurdles, Neuronetics witnessed an impressive 18% increase in the utilization of local consumables, indicating a robust demand for their groundbreaking treatments.
Strategic Mergers and Future Profitability
The company is also on the verge of a merger with Greenbrook TMS, which is expected to create significant revenue and cost synergies, ultimately driving Neuronetics towards consistent profitability post-2025. This merger is anticipated to enhance operational efficiencies while expanding the therapeutic reach and brand recognition of NeuroStar TMS therapy across broader healthcare networks.
Marketing and Community Engagement Efforts
In an ongoing effort to raise awareness of the NeuroStar therapy, Neuronetics is investing in its Better Me Guarantee Program alongside launching a television advertising campaign located in Tampa Bay, Florida. The company remains optimistic, having reaffirmed its revenue projections for 2024, estimating between $78 million and $80 million. This outlook reflects their ongoing strategic initiatives aimed at overcoming present challenges with a focus on achieving positive cash flow by 2025.
Frequently Asked Questions
What is NeuroStar TMS?
NeuroStar TMS is an FDA-cleared noninvasive treatment targeting major depressive disorder and other mental health conditions using Transcranial Magnetic Stimulation.
When was the NeuroStar TMS System FDA cleared for adolescent use?
The NeuroStar TMS System received FDA clearance for adolescents with major depressive disorder earlier this year.
What are the presentation highlights at AACAP?
The presentation will showcase groundbreaking data on TMS treatment outcomes among adolescents and young adults with major depressive disorder.
How is Neuronetics preparing for future profitability?
Neuronetics is pursuing a merger with Greenbrook TMS, aiming for enhanced operational efficiencies and revenue growth to achieve profitability by 2025.
What other treatments does NeuroStar provide?
In addition to treating adolescents with MDD, NeuroStar TMS is also FDA-cleared for adults with obsessive-compulsive disorder.
